SCHEMBL3065969

SCHEMBL3065969

NC(=O)[C@@H](O)C(=O)N1CCOCC1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.45
MMP3 P08254 1/20 0.45
MMP8 P22894 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA9 Q16790 1/20 0.43
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
TP53 P04637 1/20 0.42
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C19 P33261 1/20 0.40
PKM P14618 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
LMNA P02545 1/20 0.39
GAA P10253 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3062998 1.00 MMP1 (0.45) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL3068967 1.00 MMP1 (0.45) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL3736508 0.82 MMP1 (0.44) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL27548005 0.81 SMN1; SMN2 (0.45) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL14602765 0.78 SMN1; SMN2 (0.50) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL3986818 0.78 SMN1; SMN2 (0.47) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL9162803 0.77 SMN1; SMN2 (0.42) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL21543898 0.76 MMP1 (0.42) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL3056303 0.75 KDM4E (0.46) MMP1MMP3MMP8SMN1; SMN2CA12
SCHEMBL16964806 0.75 KDM4E (0.46) MMP1MMP3MMP8SMN1; SMN2CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267719-A1 Enhanced Indolinone Based Protein Kinase Inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2010-10-21 US disclosed
EP-1893194-A4 ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS SCRIPPS RESEARCH INST (US) 2009-07-01 EP disclosed
EP-1893194-A1 ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS The Scripps Research Institute (US) 2008-03-05 EP disclosed
US-20060287381-A1 Enhanced indolinone based protein kinase inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2006-12-21 US disclosed
WO-2006127961-A1 ENHANCED INDOLINONE BASED PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2006-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287381-A1 Enhanced indolinone based protein kinase inhibitors PHKG1, PHKG2, PRKCH MMP1 3274/4885MMP3 3506/4885MMP8 4453/4885
US-20100267719-A1 Enhanced Indolinone Based Protein Kinase Inhibitors PHKG1, PHKG2, PRKCH MMP1 3613/4885MMP3 3440/4885MMP8 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.